drugset
drugset / Trial / NCT05328557

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

NCT05328557 ↗

Phase 1 Completed 32 enrolled Cugene Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The intent of this study is to evaluate the safety and tolerability of single escalating subcutaneous doses of CUG252 in healthy adult subjects.

Timeline

Start
2021-11-09
Primary completion
2022-08-03
Completion
2022-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CUG252 Unknown — Subcutaneous

Indications

systemic lupus erythematosus